To our knowledge, this is the first study to evaluate the impact of TP53 mutation in first-line, locally advanced, and metastatic squamous cell carcinoma and non-squamous NSCLC patients treated with a combination of chemo-immunotherapy. This evidence concerns the gene TP53 and squamous cell carcinoma.